The latest price target for Karyopharm Therapeutics (NASDAQ:KPTI) was reported by RBC Capital on February 20, 2025. The analyst firm set a price target for $3.00 expecting KPTI to rise to within 12 months (a possible 392.61% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Karyopharm Therapeutics (NASDAQ:KPTI) was provided by RBC Capital, and Karyopharm Therapeutics reiterated their outperform rating.

The last upgrade for Karyopharm Therapeutics Inc happened on November 4, 2022 when RBC Capital raised their price target to $10. RBC Capital previously had a sector perform for Karyopharm Therapeutics Inc.

There is no last downgrade for Karyopharm Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karyopharm Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karyopharm Therapeutics was filed on February 20, 2025 so you should expect the next rating to be made available sometime around February 20, 2026.

While ratings are subjective and will change, the latest Karyopharm Therapeutics (KPTI) rating was a reiterated with a price target of $3.00 to $3.00. The current price Karyopharm Therapeutics (KPTI) is trading at is $0.61, which is out of the analyst’s predicted range.